Cohance Lifesciences Boosts ADC Strategy with $18M Investment in NJ Bio and Aruka Bio
Cohance Lifesciences is investing USD 13 million in its subsidiary NJ Bio, Inc. to increase its stake to 67.3%. Additionally, it is investing USD 5 million in Aruka Bio, Inc., acquiring approximately 65% ownership. Both transactions are expected to close by September 2026 and are funded by internal accruals.
The acquisitions represent a significant financial commitment (USD 18 million total) and are aimed at enhancing the company's core business strategy in the Antibody-Drug Conjugate (ADC) space, which is a high-growth area. This strategic move is likely to have a substantial impact on the company's future growth and market position.
The company is making strategic investments to strengthen its position in a key growth area (ADC therapies) by increasing its stake in a subsidiary and acquiring a controlling interest in another company. This indicates a positive outlook and strategic expansion.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced a significant step in its Antibody-Drug Conjugate (ADC) strategy through two proposed transactions approved by its Investment, Banking and Authorisations (IBA) Committee on September 3, 2026. The company will acquire an additional 244,587 shares in its subsidiary, NJ Bio, Inc., at USD 53.00 per share, totaling approximately USD 13 million. This acquisition will increase Cohance's stake in NJ Bio from 56% to 67.3%, with Dr. Naresh Jain retaining 32.7% and continuing as CEO.
Concurrently, Cohance will invest approximately USD 5 million in Aruka Bio, Inc., a step-down associate focusing on novel ADC therapies. This investment will secure approximately 65% ownership in Aruka Bio, and Dr. Naresh Jain will also assume the role of CEO at Aruka Bio. Both transactions are funded through internal accruals and are expected to be completed by the end of September 2026, subject to regulatory approvals and customary closing conditions.
This strategic reorganisation aims to strengthen Cohance’s commitment to the ADC space by integrating NJ Bio’s customer-facing capabilities with Cohance’s manufacturing platform. It also positions Aruka Bio to advance its proprietary pipeline through potential development partnerships. The company anticipates that the closer integration of NJ Bio will bolster business performance across the combined platform over time. The IBA Committee meeting took place from 4:00 p.m. to 4:55 p.m. IST.
A plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.